GLP-1 receptor agonist effects in people with type 2 diabetes using MiniMed™ advanced hybrid closed-loop therapy

被引：0
|
作者：
Shin, J. J. [1 ]
Rhinehart, A. S. [1 ]
Keiter, A. [1 ]
Ma, H. [1 ]
Cordero, T. L. [2 ]
Vigersky, R. A. [2 ]
机构：
[1] Medtron Diabet, Clin Res, Northridge, CA USA
[2] Medtron Diabet, Med Affairs, Northridge, CA USA
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
775
引用
收藏
页码：S370 / S371
页数：2
相关论文
共 50 条
  • [31] Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
    Kristina S. Boye
    Dara Stein
    Louis S. Matza
    Jessica Jordan
    Ren Yu
    Kirsi Norrbacka
    Syed Wasi Hassan
    Luis-Emilio García-Pérez
    Drugs in R&D, 2019, 19 : 213 - 225
  • [32] A Drug and Disease Model for Lixisenatide, a GLP-1 Receptor Agonist in Type 2 Diabetes
    Wilkins, Justin J.
    Dubar, Michel
    Sebastien, Bernard
    Laveille, Christian
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (03): : 267 - 278
  • [33] Timing of GLP-1 Receptor Agonist Initiation for Treatment of Type 2 Diabetes in the UK
    Boye, Kristina S.
    Stein, Dara
    Matza, Louis S.
    Jordan, Jessica
    Yu, Ren
    Norrbacka, Kirsi
    Hassan, Syed Wasi
    Garcia-Perez, Luis-Emilio
    DRUGS IN R&D, 2019, 19 (02) : 213 - 225
  • [34] Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes
    Sennik, Devesh
    Ahmed, Fahad
    Russell-Jones, David
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2012, 7 (01) : 15 - 26
  • [35] GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes
    Do, Duy
    Lee, Tiffany
    Peasah, Samuel K.
    Good, Chester B.
    Inneh, Angela
    Patel, Urvashi
    JAMA NETWORK OPEN, 2024, 7 (05)
  • [36] Dulaglutide: A GLP-1 Receptor Agonist for Once Weekly Treatment of Type 2 Diabetes
    Heitmann, E.
    Jung, H.
    Schloot, N.
    Pavo, I.
    Forst, T.
    Trautmann, M.
    Schernthaner, G.
    DIABETOLOGIE UND STOFFWECHSEL, 2016, 11 (06) : 398 - 417
  • [37] GLP-1 receptor agonist confer target organ protection in type 2 diabetes
    Bonnet, Fabrice
    DIABETES & METABOLISM, 2017, 43 : 2S1 - 2S2
  • [38] Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy
    Bzowyckyj, Andrew
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2020, 45 : 7 - 16
  • [39] Adjunct GLP-1 receptor agonist use in patients with Type 1 Diabetes
    Harkin, P.
    Crowley, R.
    McKenna, M.
    Canavan, R.
    Callanan, I
    Connolly, M.
    O'Shea, D.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2018, 187 : S205 - S205
  • [40] Comparison of extended release GLP-1 receptor agonist therapy versus sitagliptin in the management of type 2 diabetes
    Stolar, Mark W.
    Grimm, Michael
    Chen, Steve
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2013, 6 : 435 - 444
12345